ClinicalTrials.gg

Esophageal Neoplasms clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,874 studies for Esophageal Neoplasms across more than 10 countries. 503 are recruiting or about to start. 1,148 of them are mainly about Esophageal Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Esophageal Squamous Cell Carcinoma: 2,549 studies, 786 open.

ClinicalTrials.gov finds 3,139 studies for Esophageal Neoplasms. How that becomes 1,874 here

This page counts the studies the registry files under Esophageal Neoplasms, and those it files under no condition that list Esophageal Neoplasmsthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 3,139Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −597Filed under a narrower condition, counted on its own pageEsophageal Squamous Cell Carcinoma 476 · Adenocarcinoma Of Esophagus 114
  3. −8List Esophageal Neoplasms as a condition, but the registry did not file them under itMost often written as “Gastro-esophageal Cancer” (2), “Advanced Esophageal Cancers” (1), and “Lower Esophageal Cancer” (1). The registry filed them under other conditions only, most often Neoplasms (3) and Carcinoma, Non-Small-Cell Lung (2).
  4. −662Match it another way66 name it in the title, 7 in a keyword, and 589 by a synonym or other text the search reads.
  5. 1,872Counted here and found by its search29 of them list Esophageal Neoplasms in their own words; the registry filed them under no condition.
  6. +2
    Counted here, but its search does not find them
  7. 1,874The count on this page

Status

Completed
749
Recruiting
388
Status unknown
292
Terminated
167
Active, not recruiting
106
Not yet recruiting
103

Phase

Phase 2
627
Phase 1
386
Phase 3
138
Phase 4
29
Early Phase 1
11

Where

United States
676
China
502
United Kingdom
111
France
93
Netherlands
90
Germany
84

Who develops what

Add Esophageal Neoplasms to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 36 programs from 28 companies, 9 with this as their studies’ main aim; 3 with a live phase 3 study; 5 primary completions in the next 12 months. Compare Pfizer, 3SBio and AstraZeneca here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Aug 2023
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2023
  • NCT05070247 · Takeda · Phase 2 · background · “Pembrolizumab” · registered Sep 2021
  • NCT04430738 · Pfizer · Phase 2 · live · background · “pembrolizumab” · registered Jun 2020
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)33 studies
FluorouracilRecent, repeated
Evidence
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “5-Fluorouracil” · registered Jan 2026
  • NCT06469944 · Merck & Co., Inc · Phase 2 · live · background · “5-Fluorouracil (5-FU)” · registered Jun 2024
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “5-FU” · registered Jul 2023
  • NCT05152147 · Jazz Pharmaceuticals · Phase 3 · live · background · “5-Fluorouracil” · registered Nov 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “5-Fluorouracil” · registered Aug 2021
Sanofi20% of its industry studiesUS: off-patent, 19 generics marketed33 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Oxaliplatin” · registered Jan 2026
  • NCT06469944 · Merck & Co., Inc · Phase 2 · live · comparator · “Oxaliplatin” · registered Jun 2024
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Oxaliplatin” · registered Jul 2023
  • NCT05152147 · Jazz Pharmaceuticals · Phase 3 · live · background · “Oxaliplatin” · registered Nov 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Oxaliplatin” · registered Aug 2021
Sanofi35% of its industry studies33 studies
LeucovorinRecent, repeated
Evidence
  • NCT07431281 · AstraZeneca · Phase 3 · live · comparator · “Leucovorin” · registered Jan 2026
  • NCT06469944 · Merck & Co., Inc · Phase 2 · live · background · “Leucovorin” · registered Jun 2024
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Leucovorin” · registered Jul 2023
  • NCT04430738 · Pfizer · Phase 2 · live · background · “leucovorin” · registered Jun 2020
  • NCT03929666 · Jazz Pharmaceuticals · Phase 2 · background · “Leucovorin” · registered Feb 2019
Sanofi15% of its industry studiesUS: off-patent, 24 generics marketed33 studies
IrinotecanRecent, repeated
Evidence
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Irinotecan” · registered Jul 2023
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Irinotecan (Camptosar)” · registered Oct 2022
  • NCT05342636 · Merck & Co., Inc · Phase 2 · background · “Irinotecan” · registered Apr 2022
  • NCT05319730 · Merck & Co., Inc · Phase 2 · live · comparator · “Irinotecan” · registered Apr 2022
  • NCT04415853 · Sunshine Lake Pharma Co., Ltd. · Phase 3 · live · comparator · “Irinotecan/Tegafur” · registered May 2020
Pfizer17% of its industry studiesUS: off-patent, 7 generics marketedEU: Les Laboratoires des Médicaments Stériles (EMA 2016)34 studies
CapecitabineRecent, repeated
Evidence
  • NCT07431281 · AstraZeneca · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
  • NCT06469944 · Merck & Co., Inc · Phase 2 · live · background · “Capecitabine” · registered Jun 2024
  • NCT05152147 · Jazz Pharmaceuticals · Phase 3 · live · background · “Capecitabine” · registered Nov 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Aug 2021
  • NCT04430738 · Pfizer · Phase 2 · live · background · “capecitabine” · registered Jun 2020
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized22 studies
DocetaxelRecent, repeated
Evidence
  • NCT05592626 · Marengo Therapeutics, Inc. · Phase 2 · live · background · “Docetaxel (Taxotere)” · registered Oct 2022
  • NCT05383482 · Laekna Limited · Phase 2 · background · “Docetaxel” · registered Apr 2022
  • NCT05094336 · Amgen · Phase 2 · live · background · “Docetaxel” · registered Oct 2021
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Docetaxel” · registered Aug 2021
  • NCT04140526 · OncoC4, Inc. · Phase 2 · live · background · “Docetaxel” · registered Oct 2019
Sanofi27% of its industry studiesUS: off-patent, 13 generics marketedEU: off-patent, 2 generics authorized22 studies
PaclitaxelRecent, repeated
Evidence
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Paclitaxel” · registered Aug 2023
  • NCT05342636 · Merck & Co., Inc · Phase 2 · background · “Paclitaxel” · registered Apr 2022
  • NCT05319730 · Merck & Co., Inc · Phase 2 · live · comparator · “Paclitaxel” · registered Apr 2022
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Paclitaxel” · registered Aug 2021
  • NCT04540211 · Hoffmann-La Roche · Phase 3 · background · “Paclitaxel” · registered Sep 2020
Hoffmann-La Roche12% of its industry studiesUS: off-patent, 10 generics marketed23 studies
NivolumabRecent, repeated
Evidence
  • NCT07431281 · AstraZeneca · Phase 3 · live · background · “Nivolumab” · registered Jan 2026
  • NCT06047379 · Neonc Technologies, Inc. · Phase 2 · live · background · “Nivolumab” · registered Aug 2023
  • NCT03241173 · Incyte Corporation · Phase 2 · background · “Nivolumab” · registered Aug 2017
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)22 studies
LevoleucovorinRecent, repeated
Evidence
  • NCT06469944 · Merck & Co., Inc · Phase 2 · live · background · “Levoleucovorin” · registered Jun 2024
  • NCT05945823 · Otsuka Holdings Co., Ltd. · Phase 2 · live · background · “Levoleucovorin” · registered Jul 2023
Aurobindo Pharma100% of its industry studies22 studies

20 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
Fluorine F 18 FAPI-74☆ Track1 live phase-3 study: NCT07217704SOFIE

The 1 in phase 3 with the nearest primary completion, of 36 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (5)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • Dec 2026 est.SSGJ-706, xelox · 3SBio Inc. · Phase 2 registry mapping onlyNCT07233850 A Phase II Clinical Study Evaluating SSGJ-706 in Combination Therapy for Advanced Gastrointestinal Cancers — primary endpoint: Incidence and severity of Adverse Events · 300 enrolled
  • 1 Jan 2027 est.SL-28 · Second Life Therapeutics · Phase 2 main aimNCT07341737 SL-28 for Advanced Solid Tumours — primary endpoint: Number of participants with treatment-emergent adverse events · 60 enrolled
  • Feb 2027 est.TQB6411 · Sino Biopharmaceutical Limited · Phase 2 main aimNCT07367516 Clinical Trial Evaluating TQB6411 Injection in Participant s With Esophageal Cancer — primary endpoint: Recommended Phase 2 Dose (RP2D) · 105 enrolled

2 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Esophageal Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 63 open · Antimitotic agents 12 open · Tyrosine kinase inhibitors (TKIs) 11 open · Antibody-drug conjugates (ADCs) 6 open · Antimetabolites 4 open

Coming up

166studies finish main data collection within a year8 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 388 Esophageal Neoplasms studies recruiting now, 246 (63%) set no upper age limit and 75 (19%) stop at 75 or younger. 20 (5%) take children under 18. 2 (1%) are for women only and 1 (<1%) for men only; 36 (9%) take healthy volunteers.

Recruiting studies that take each age, of 388
AgeWomenMen
1015 (4%)15 (4%)
18350 (90%)349 (90%)
30369 (95%)368 (95%)
40373 (96%)372 (96%)
50375 (97%)374 (96%)
65376 (97%)375 (97%)
75370 (95%)369 (95%)
85287 (74%)286 (74%)

Across all 1,874 studies, recruiting or not: 18% stop at 75 or younger and 1% at 65; 6% take children; <1% are for women only and <1% for men only; 6% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Esophageal Neoplasms studies take

Of 198 phase 2 interventional studies under Esophageal Neoplasms, half reached primary completion within 52 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 148 mo29–76 · 126 studies51 mo34–70 · 78 studies40 mo25–76 · 48 studies
Phase 1/261 mo43–92 · 74 studies——
Phase 252 mo33–78 · 198 studies—55 mo33–85 · 174 studies
Phase 361 mo34–113 · 57 studies——
Interventional, no phase46 mo23–96 · 218 studies—46 mo23–96 · 209 studies
Observational64 mo33–252 · 174 studies—81 mo32–252 · 152 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Stopped1

Studies

Recruiting first, then most recently updated. Showing 50 of 1,874. Browse all 1,874 → or search them.